Pharmaceutical Family-owned German pharma major Boehringer Ingelheim today announced an expanded UK indication for Spiriva (tiotropium) Respimat as add-on maintenance bronchodilator treatment in patients aged six years and older with severe asthma who experienced one or more severe asthma exacerbations in the past year, following the European Union regulatory acceptance in March 2018. 7 June 2018